Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Vaccines
Filter     Order     Display # 
Date Item Title Hits
01 Sep 2010 Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP 23
30 Aug 2010 Two Thirds of Study Volunteers Respond to First-Ever "Re-Vaccination" of Vacc-4x, Bionor Pharma's Peptide-Based Therapeutic HIV-Vaccine 42
26 Aug 2010 The Fourth Product Candidate Containing Antigenics' QS-21 In Phase 3 Clinical Development 73
26 Aug 2010 FDA Accepts Sanofi Pasteur's Application to Expand Indication of Menactra Vaccine to Infants and Toddlers 62
24 Aug 2010 GSK European Commission amends licence for Cervarix 29
18 Aug 2010 Advaxis Completes Dosing Vanguard Group in Phase II Cervical Dysplasia (CIN) Study 67
17 Aug 2010 MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute 14
17 Aug 2010 BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine 78
17 Aug 2010 Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Programas in Japan 37
16 Aug 2010 Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation 58
12 Aug 2010 Novavax Reports Positive Results from Pre-Clinical Safety Study of Respiratory Syncytial Virus (RSV) Vaccine Candidate 86
11 Aug 2010 Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac(R)-based AIDS Vaccine 83
11 Aug 2010 Emergent BioSolutions and Temasek Life Sciences Ventures Establish Joint Venture to Develop Broad Spectrum Pandemic Flu Vaccine and Therapeutic 85
10 Aug 2010 Nabi Biopharmaceuticals Completes Third PentaStaph(TM) Milestone 66
04 Aug 2010 TapImmune Signs Research and Technology License Option Agreement for Smallpox Vaccine 53
03 Aug 2010 Long-Term Follow-Up of DCVax®-Treated Brain Cancer Patients Shows 33% of Patients Reached 4-Year Survival and 27% Have Reached or Exceeded 6-Year Survival 80
03 Aug 2010 Advaxis Gets Formal Go-Ahead from India's DCGI to Conduct Phase II Cervical Cancer Trial 65
02 Aug 2010 FDA Approves Vaccines for the 2010-2011 Influenza Season 93
28 Jul 2010 Oxford BioMedica Announces FDA Approval for TroVax Phase II Study in Prostate Cancer 170
28 Jul 2010 Etubics Enters Phase I Cancer Clinical Trials Focused on Colorectal Cancer 75
28 Jul 2010 Advaxis Phase I Survival Update 76
27 Jul 2010 Sinopharm and Merck Sign Statement of Mutual Intent 16
27 Jul 2010 Dynavax Completes Enrollment and First Immunizations in Universal Flu Vaccine Study 66
27 Jul 2010 Antigenics Presents Positive, Top Line Data from Phase I Herpes Clinical Trial 83
26 Jul 2010 FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID, Targeting Mantle Cell Lymphoma 71
26 Jul 2010 Vical's Herpes Simplex Vaccines Protect Against Lethal Challenge and Demonstrate Significant Therapeutic Benefit in Animal Models 63
22 Jul 2010 MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma 90
19 Jul 2010 Immunacia's Genetic Immunity Reports Phase II Data on DermaVir, a Therapeutic Vaccine for HIV/AIDS, During the XVIII International AIDS Conference: A 70% Viral Load Reduction Demonstrated in HIV Drug-naïve Individuals 102
19 Jul 2010 Phase II Data from FIT Biotech's HIV Immunotherapy Show Reduction in Viral Load and Increase in CD4 Cell Count 91
19 Jul 2010 Argos Therapeutics' Arcelis HIV Immunotherapy Demonstrates Significant Reduction in Viral Load and Delay in Viral Rebound Kinetics in Interim Analysis of Phase 2 Study 87
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1123

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease

Order Now

Recommended Report

R&D Drug Pipeline Database
Order Now

Subscribe La Merie Biologics